182 related articles for article (PubMed ID: 30670411)
1. Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing
Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670411
[TBL] [Abstract][Full Text] [Related]
2. Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model.
Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
Int J Antimicrob Agents; 2020 Feb; 55(2):105838. PubMed ID: 31705960
[TBL] [Abstract][Full Text] [Related]
3.
Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
5. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
[TBL] [Abstract][Full Text] [Related]
6. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
[TBL] [Abstract][Full Text] [Related]
7. In vivo study assessed meropenem and amikacin combination therapy against carbapenem-resistant and carbapenemase-producing Enterobacteriaceae strains.
Hagihara M; Kato H; Yamashita R; Soda M; Watanabe H; Sakanashi D; Shiota A; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Kitaichi K; Mikamo H
J Infect Chemother; 2020 Jan; 26(1):1-7. PubMed ID: 31735629
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
[TBL] [Abstract][Full Text] [Related]
9. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
10. Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae.
Mushtaq S; Vickers A; Woodford N; Haldimann A; Livermore DM
J Antimicrob Chemother; 2019 Apr; 74(4):953-960. PubMed ID: 30590470
[TBL] [Abstract][Full Text] [Related]
11.
Lasko MJ; Abdelraouf K; Nicolau DP
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431414
[TBL] [Abstract][Full Text] [Related]
12. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an
Sabet M; Tarazi Z; Rubio-Aparicio D; Nolan TG; Parkinson J; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133570
[TBL] [Abstract][Full Text] [Related]
13. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
Bhalodi AA; Crandon JL; Williams G; Nicolau DP
Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
Lasko MJ; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2021 Aug; 76(9):2310-2316. PubMed ID: 34096601
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.
Wiskirchen DE; Crandon JL; Furtado GH; Williams G; Nicolau DP
Antimicrob Agents Chemother; 2011 Jul; 55(7):3220-5. PubMed ID: 21518838
[TBL] [Abstract][Full Text] [Related]
16. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
MacVane SH; Crandon JL; Nichols WW; Nicolau DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999
[TBL] [Abstract][Full Text] [Related]
17. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.
Castanheira M; Rhomberg PR; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386
[TBL] [Abstract][Full Text] [Related]
18. The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli.
Roach EJ; Uehara T; Daigle DM; Six DA; Khursigara CM
Microbiol Spectr; 2021 Oct; 9(2):e0091821. PubMed ID: 34494877
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Hirai J; Asai N; Suematsu H; Yamagishi Y; Mikamo H
Antibiotics (Basel); 2021 Sep; 10(10):. PubMed ID: 34680760
[TBL] [Abstract][Full Text] [Related]
20. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
